Controlling Arteriogenesis and Mast Cells Are Central to Bioengineering Solutions for Critical Bone Defect Repair Using Allografts
Although most fractures heal, critical defects in bone fail due to aberrant differentiation of mesenchymal stem cells towards fibrosis rather than osteogenesis. While conventional bioengineering solutions to this problem have focused on enhancing angiogenesis, which is required for bone formation, r...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2016-01-01
|
| Series: | Bioengineering |
| Subjects: | |
| Online Access: | http://www.mdpi.com/2306-5354/3/1/6 |
| _version_ | 1797763209727311872 |
|---|---|
| author | Ben Antebi Longze Zhang Dmitriy Sheyn Gadi Pelled Xinping Zhang Zulma Gazit Edward M. Schwarz Dan Gazit |
| author_facet | Ben Antebi Longze Zhang Dmitriy Sheyn Gadi Pelled Xinping Zhang Zulma Gazit Edward M. Schwarz Dan Gazit |
| author_sort | Ben Antebi |
| collection | DOAJ |
| description | Although most fractures heal, critical defects in bone fail due to aberrant differentiation of mesenchymal stem cells towards fibrosis rather than osteogenesis. While conventional bioengineering solutions to this problem have focused on enhancing angiogenesis, which is required for bone formation, recent studies have shown that fibrotic non-unions are associated with arteriogenesis in the center of the defect and accumulation of mast cells around large blood vessels. Recently, recombinant parathyroid hormone (rPTH; teriparatide; Forteo) therapy have shown to have anti-fibrotic effects on non-unions and critical bone defects due to inhibition of arteriogenesis and mast cell numbers within the healing bone. As this new direction holds great promise towards a solution for significant clinical hurdles in craniofacial reconstruction and limb salvage procedures, this work reviews the current state of the field, and provides insights as to how teriparatide therapy could be used as an adjuvant for healing critical defects in bone. Finally, as teriparatide therapy is contraindicated in the setting of cancer, which constitutes a large subset of these patients, we describe early findings of adjuvant therapies that may present future promise by directly inhibiting arteriogenesis and mast cell accumulation at the defect site. |
| first_indexed | 2024-03-12T19:38:17Z |
| format | Article |
| id | doaj.art-4c761afb88144660babd3b5f66a9fc99 |
| institution | Directory Open Access Journal |
| issn | 2306-5354 |
| language | English |
| last_indexed | 2024-03-12T19:38:17Z |
| publishDate | 2016-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Bioengineering |
| spelling | doaj.art-4c761afb88144660babd3b5f66a9fc992023-08-02T04:01:25ZengMDPI AGBioengineering2306-53542016-01-0131610.3390/bioengineering3010006bioengineering3010006Controlling Arteriogenesis and Mast Cells Are Central to Bioengineering Solutions for Critical Bone Defect Repair Using AllograftsBen Antebi0Longze Zhang1Dmitriy Sheyn2Gadi Pelled3Xinping Zhang4Zulma Gazit5Edward M. Schwarz6Dan Gazit7US Army Institute of Surgical Research, Multi-Organ Support Technology, 3698 Chambers Pass, Fort Sam Houston, TX 78234, USACenter for Musculoskeletal Research, University of Rochester, 601 Elmwood Avenue, Rochester, NY 14642, USADepartment of Surgery, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USADepartment of Surgery, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USACenter for Musculoskeletal Research, University of Rochester, 601 Elmwood Avenue, Rochester, NY 14642, USADepartment of Surgery, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USACenter for Musculoskeletal Research, University of Rochester, 601 Elmwood Avenue, Rochester, NY 14642, USADepartment of Surgery, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USAAlthough most fractures heal, critical defects in bone fail due to aberrant differentiation of mesenchymal stem cells towards fibrosis rather than osteogenesis. While conventional bioengineering solutions to this problem have focused on enhancing angiogenesis, which is required for bone formation, recent studies have shown that fibrotic non-unions are associated with arteriogenesis in the center of the defect and accumulation of mast cells around large blood vessels. Recently, recombinant parathyroid hormone (rPTH; teriparatide; Forteo) therapy have shown to have anti-fibrotic effects on non-unions and critical bone defects due to inhibition of arteriogenesis and mast cell numbers within the healing bone. As this new direction holds great promise towards a solution for significant clinical hurdles in craniofacial reconstruction and limb salvage procedures, this work reviews the current state of the field, and provides insights as to how teriparatide therapy could be used as an adjuvant for healing critical defects in bone. Finally, as teriparatide therapy is contraindicated in the setting of cancer, which constitutes a large subset of these patients, we describe early findings of adjuvant therapies that may present future promise by directly inhibiting arteriogenesis and mast cell accumulation at the defect site.http://www.mdpi.com/2306-5354/3/1/6critical bone defectarteriogenesisosteogenesisfibrosismast cellsrecombinant parathyroid hormone (rPTHteriparatideForteo) |
| spellingShingle | Ben Antebi Longze Zhang Dmitriy Sheyn Gadi Pelled Xinping Zhang Zulma Gazit Edward M. Schwarz Dan Gazit Controlling Arteriogenesis and Mast Cells Are Central to Bioengineering Solutions for Critical Bone Defect Repair Using Allografts Bioengineering critical bone defect arteriogenesis osteogenesis fibrosis mast cells recombinant parathyroid hormone (rPTH teriparatide Forteo) |
| title | Controlling Arteriogenesis and Mast Cells Are Central to Bioengineering Solutions for Critical Bone Defect Repair Using Allografts |
| title_full | Controlling Arteriogenesis and Mast Cells Are Central to Bioengineering Solutions for Critical Bone Defect Repair Using Allografts |
| title_fullStr | Controlling Arteriogenesis and Mast Cells Are Central to Bioengineering Solutions for Critical Bone Defect Repair Using Allografts |
| title_full_unstemmed | Controlling Arteriogenesis and Mast Cells Are Central to Bioengineering Solutions for Critical Bone Defect Repair Using Allografts |
| title_short | Controlling Arteriogenesis and Mast Cells Are Central to Bioengineering Solutions for Critical Bone Defect Repair Using Allografts |
| title_sort | controlling arteriogenesis and mast cells are central to bioengineering solutions for critical bone defect repair using allografts |
| topic | critical bone defect arteriogenesis osteogenesis fibrosis mast cells recombinant parathyroid hormone (rPTH teriparatide Forteo) |
| url | http://www.mdpi.com/2306-5354/3/1/6 |
| work_keys_str_mv | AT benantebi controllingarteriogenesisandmastcellsarecentraltobioengineeringsolutionsforcriticalbonedefectrepairusingallografts AT longzezhang controllingarteriogenesisandmastcellsarecentraltobioengineeringsolutionsforcriticalbonedefectrepairusingallografts AT dmitriysheyn controllingarteriogenesisandmastcellsarecentraltobioengineeringsolutionsforcriticalbonedefectrepairusingallografts AT gadipelled controllingarteriogenesisandmastcellsarecentraltobioengineeringsolutionsforcriticalbonedefectrepairusingallografts AT xinpingzhang controllingarteriogenesisandmastcellsarecentraltobioengineeringsolutionsforcriticalbonedefectrepairusingallografts AT zulmagazit controllingarteriogenesisandmastcellsarecentraltobioengineeringsolutionsforcriticalbonedefectrepairusingallografts AT edwardmschwarz controllingarteriogenesisandmastcellsarecentraltobioengineeringsolutionsforcriticalbonedefectrepairusingallografts AT dangazit controllingarteriogenesisandmastcellsarecentraltobioengineeringsolutionsforcriticalbonedefectrepairusingallografts |